SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MJ who wrote (1112)10/24/1998 3:22:00 PM
From: Brian Thomas Hertzog  Read Replies (1) of 1510
 
Oct 19, 1998 Van Kasper & Co (IMNR $12 13/16, Strong Buy) forthewise
(M/Minneapolis) Oct 24 1998 3:18PM EDT
As stated in our initiation of coverage report June 23, we estimated that the agreement would allow IMNR to receive as much as $77 million over the next two years. This includes license and milestone payments of $45 million, development support of $18 million and the purchase of $14 million of IMNR stock priced at a 20-50% premium to the market (the initial purchase involved $2 million of stock purchased at $16.91 per share). The agreement calls for a 50/50 split of the profits from Remune between the two companies.

We continue to believe that IMNR will benefit from its collaboration with Agouron. Furthermore, we believe that this partnership: 1) reduces IMNR's risk; 2) offers a third party validation of Remune; 3) eliminated the need for IMNR to build a sales and marketing force; and 4) allows the Company to benefit from regulatory experience of a pharmaceutical company that has already gotten an HIV drug approved by the FDA.

We reiterate our Strong Buy on the shares of IMNR


Oct 7, 1998 Van Kasper & Co (IMNR $12 7/8, Strong Buy) forthewise
(M/Minneapolis) Oct 24 1998 2:58PM EDT
We believe that the positive price action in the shares of IMNR was due to two factors:
1. Speculation that because the upcoming road show was cancelled, the Company may be in the midst of merger talks, and
2. In anticipation of a possible announcement of clinical trial results of the Company's HIV drug Remune in combination with other antiviral drugs.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News